Jefferies Initiates Coverage On Celcuity with Buy Rating, Announces Price Target of $48
Jefferies analyst Maury Raycroft initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of $48.
Celcuity Q2 EPS $(0.66) Down From $(0.17) YoY
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.66) per share. This is a 288.24 percent decrease over losses of $(0.17) per share from the same period last year.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
22 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.